The offering includes five tranches of notes

Davis Polk advised the representatives of the underwriters, in connection with the offering of $8 billion aggregate principal amount of notes issued by Merck & Co., Inc. The notes were offered in five tranches, maturing in 2027, 2028, 2031, 2051 and 2061. This offering includes Merck’s debut sustainability notes issuance.

Merck is a global healthcare company that delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. For over 130 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of its mission to save and improve lives. The company demonstrates its commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to prevent and treat diseases that threaten people and animals – including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases – as it aspires to be the premier research-intensive biopharmaceutical company in the world.

The Davis Polk capital markets team included partner Byron B. Rooney, counsel Jennifer Ying Lan and associates Livia Maas and Eric Wall. The tax team included partner Michael Farber and associate Justin Corvino. All members of the Davis Polk team are based in the New York office.